Podcast: Bringing diversity to Alzheimer’s trials
In recent years, the Alzheimer’s disease market has seen several developments, including the debut of the first disease-modifying therapies (DMTs),…
Central Nervous System
-
-
BioVie stock sinks on Phase IIb Parkinson’s trial data
BioVie’s stock crashed after the biotech released data from its Phase IIb Parkinson’s disease trial that used a unique composite…
-
Schizophrenia “non-responders” may need more time, study finds
A research study has indicated that researchers should better consider time differences between individual symptom improvement during schizophrenia clinical trials.…
-
MapLight Therapeutics stock crashes on Phase II schizophrenia data
MapLight Therapeutics’ stock crashed by more than 70% after the release of data from its Phase II schizophrenia trial, despite…
-
Loneliness interventions do not have strong sustained effects on memory function
Loneliness, defined as a subjective experience of a discrepancy between the preferred interpersonal relationship an individual has and their actual…
-
AAIC26: Biogen stock drops after unveiling tau-targeting ASO data
Biogen’s stock has dropped after it released mixed data on its tau-targeting investigational antisense oligonucleotide (ASO), compounding a previous announcement…
-
Alkermes releases nine-month data as OX2R race heats up
Alkermes’ oral, selective orexin 2 receptor (OX2R) agonist has shown continued benefit nine months after the start of treatment in…
-
Roche culls development of two Huntington’s disease programmes
Roche has stopped development of two of its Huntington’s disease candidates after one failed to show benefit in a Phase…
-
Compass’ psilocybin shows six-month durability in Phase III trial
Compass Pathways’ psilocybin-based therapy has continued to show benefit after six months in a Phase III trial in treatment-resistant depression…
-
EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s
AbbVie's ROSSINI (NCT06107426) study of its Parkinson's disease combination, Vyalev, has shown promise in a 12-month analysis. The data, which…
